These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24607774)

  • 1. Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies.
    Reichetzeder C; Tsuprykov O; Hocher B
    Life Sci; 2014 Nov; 118(2):141-8. PubMed ID: 24607774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of endothelin and endothelin receptor antagonists in renal disease.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():78-88. PubMed ID: 16919017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrasentan for the treatment of diabetic nephropathy.
    Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
    Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Et and diabetic nephropathy: preclinical and clinical studies.
    Gagliardini E; Zoja C; Benigni A
    Semin Nephrol; 2015 Mar; 35(2):188-96. PubMed ID: 25966350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endothelin system and endothelin receptor antagonists.
    Jandeleit-Dahm KA; Watson AM
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):66-71. PubMed ID: 22123210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of endothelin receptor antagonism in kidney disease.
    Czopek A; Moorhouse R; Webb DJ; Dhaun N
    Am J Physiol Regul Integr Comp Physiol; 2016 Mar; 310(5):R388-97. PubMed ID: 26702154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin and endothelin antagonists in chronic kidney disease.
    Kohan DE; Barton M
    Kidney Int; 2014 Nov; 86(5):896-904. PubMed ID: 24805108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin Receptor Antagonists: New Hope for Renal Protection?
    Tobe S; Kohan DE; Singarayer R
    Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
    Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptors, renal effects and blood pressure.
    Boesen EI
    Curr Opin Pharmacol; 2015 Apr; 21():25-34. PubMed ID: 25544397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
    Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
    Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin antagonism and hypertension: an evolving target.
    Laffin LJ; Bakris GL
    Semin Nephrol; 2015 Mar; 35(2):168-75. PubMed ID: 25966348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endothelin receptor antagonists--a brief description of the new class of drugs].
    Kowalczyk A; Kołodziejczyk M; Gorąca A
    Postepy Hig Med Dosw (Online); 2014 Jan; 68():1076-80. PubMed ID: 25228516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin antagonists in clinical trials: lessons learned.
    Barton M; Kohan DE
    Contrib Nephrol; 2011; 172():255-260. PubMed ID: 21894005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure.
    Pfab T; Thöne-Reineke C; Theilig F; Lange I; Witt H; Maser-Gluth C; Bader M; Stasch JP; Ruiz P; Bachmann S; Yanagisawa M; Hocher B
    J Am Soc Nephrol; 2006 Apr; 17(4):1082-9. PubMed ID: 16495378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelin in hypertension.
    Schiffrin EL
    Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin and tubulointerstitial renal disease.
    Ong AC; von Websky K; Hocher B
    Semin Nephrol; 2015 Mar; 35(2):197-207. PubMed ID: 25966351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin, nitric oxide, and reactive oxygen species in diabetic kidney disease.
    Pollock JS; Pollock DM
    Contrib Nephrol; 2011; 172():149-159. PubMed ID: 21893996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.